# EDGAR Filing Document

**Accession Number:** 0001708688
**File Stem:** 0001140361-26-016378
**Filing Date:** 2026-4
**Character Count:** 11097
**Document Hash:** 41af7cc2bc57929d910cafa7e4a78257
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-016378.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001140361-26-016378

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260423

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InflaRx N.V.
- **CENTRAL INDEX KEY:** 0001708688
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38283
- **FILM NUMBER:** 26888822

**BUSINESS ADDRESS:**
- **STREET 1:** WINZERLAER STR. 2
- **CITY:** JENA
- **STATE:** 2M
- **ZIP:** 07745
- **BUSINESS PHONE:** 49 3641 508180

**MAIL ADDRESS:**
- **STREET 1:** WINZERLAER STR. 2
- **CITY:** JENA
- **STATE:** 2M
- **ZIP:** 07745

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fireman B.V.
- **DATE OF NAME CHANGE:** 20170606

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 6-K

------

#### Report of Foreign Private Issuer

#### Pursuant to Rule 13a-16 or 15d-16

#### of the Securities Exchange Act of 1934

#### For the month of April 2026

#### Commission File Number: 001-38283

#### <br>

------

## InflaRx N.V.

(Translation of registrant's name into English)

------

#### Winzerlaer Str. 2

#### 07745 Jena, Germany
(Address of principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

#### INFLARX N.V.

#### Results of Annual General Meeting of Shareholders

On April 23, 2026, InflaRx N.V. (the "Company") held its Annual General Meeting of Shareholders (the "Annual General Meeting"). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

**<u>Agenda Item 3.</u>** Adoption of Dutch statutory annual accounts for the financial year ended December 31, 2025.

The Company shareholders approved the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2025.

**<u>Agenda Item 5.</u>** Instruction to KPMG Accountants N.V. for the external audit of the Company's statutory annual accounts for the financial year 2026.

The Company shareholders approved the instruction to KPMG Accountants N.V. for the external audit of the Company's statutory annual accounts for the financial year 2026.

**<u>Agenda Item 6.</u>** Release from liability for the Company's directors with respect to the performance of their duties during the financial year ended December 31, 2025.

The Company shareholders approved the release from liability for the Company's directors with respect to the performance of their duties during the financial year ended December 31, 2025.

**<u>Agenda Item 7.</u>** Re-appointment of Mr. Niels Riedemann as executive director of the Company.

The Company shareholders approved the re-appointment of Mr. Niels Riedemann as executive director of the Company.

**<u>Agenda Item 8.</u>** Re-appointment of Mr. Renfeng Guo as executive director of the Company.

The Company shareholders approved the re-appointment of Mr. Renfeng Guo as executive director of the Company.

**<u>Agenda Item 9.</u>** Re-appointment of Mr. Nicolas Fulpius as non-executive director of the Company.

The Company shareholders approved the re-appointment of Mr. Nicolas Fulpius as non-executive director of the Company.

**<u>Agenda Item 10.</u>** Re-appointment of Mr. Richard Brudnick as non-executive director of the Company.

The Company shareholders approved the re-appointment of Mr. Richard Brudnick as non-executive director of the Company.

**<u>Agenda Item 11.</u>** Re-appointment of Ms. Hege Hellstrom as non-executive director of the Company.

The Company shareholders approved the re-appointment of Ms. Hege Hellstrom as non-executive director of the Company.

**<u>Agenda Item 12.</u>** Extension of authorization for the Company's board of directors (the "Board") to issue shares and grant rights to subscribe for shares.

------

The Company shareholders approved the extension of authorization for the Company's Board to issue shares and grant rights to subscribe for shares.

**<u>Agenda Item 13.</u>** Extension of authorization for the Board to limit and exclude pre-emption rights.

The Company shareholders approved the extension of authorization for the Board to limit and exclude pre-emption rights.

**<u>Agenda Item 14.</u>** Extension of authorization for the Board to acquire shares and depository receipts for shares in the Company's capital.

The Company shareholders approved the extension of authorization for the Board to acquire shares and depository receipts for shares in the Company's capital.

**<u>Agenda Item 15.</u>** Amendment to the Company's articles of association.

The Company shareholders approved the amendment to the Company's articles of association.

**<u>Agenda Item 16.</u>** Approval of a new Long-Term Incentive Plan (the "LTIP 2026").

The Company shareholders approved the LTIP 2026. <br>

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INFLARX N.V.** | **INFLARX N.V.** |
| Date: April 23, 2026 | By: | /s/ Niels Riedemann |
|  | Name: | Niels Riedemann |
|  | Title: | Chief Executive Officer |

---

------

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Deed of Amendment to the Articles of Association, dated April 23, 2026.](ef20071058_ex99-1.htm) |

---

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

** 

<br> ---

| | |
|:---|:---|
| ![](image00001.jpg) | ![](image00001.jpg) |
|  | 1 |

---

** 

<br> *This is a translation into English of the deed of amendment to the articles of association of a public limited liability company under Dutch law. In the event of a conflict between the English and Dutch texts, the Dutch text shall prevail.*

#### DEED OF AMENDMENT TO THE ARTICLES OF ASSOCIATION OF

#### INFLARX N.V.

On this, the [twenty-third day of April] two thousand and twenty-six, appeared before me, Paul Cornelis Simon van der Bijl, civil law notary in Amsterdam:

[***ND employee, under proxy***], working at the offices of NautaDutilh N.V. located at Beethovenstraat 400, 1082 PR Amsterdam.

The person appearing before me declared that the general meeting of shareholders of **InflaRx N.V.**, a public limited liability company (*naamloze vennootschap*) under Dutch law, having its corporate seat in Amsterdam, the Netherlands (address: Winzerlaer Strasse 2, 07745 Jena, Germany, trade register number: 68904312) (the "**Company**"), held at Amsterdam, the Netherlands, on the [twenty-third day of April] two thousand and twenty-six has resolved to partially amend the Company's articles of association (the "**Articles of Association**").

The Articles of Association were most recently amended by a deed executed on the twenty-fourth day of April two thousand and twenty-five before a deputy of Paul Cornelis Simon van der Bijl, aforementioned civil law notary.

Further to this resolution the person appearing stated that the Articles of Association are amended as follows:

**I.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Article 4 paragraph 1 will be:**

---

| | |
|:---|:---|
| "**4.1** | The Company's authorised share capital amounts to forty-three million three hundred and seventy-five thousand two hundred euro (EUR 43,375,200.00).". |

---

**II.**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Article 4 paragraph 2 will be:**

---

| | |
|:---|:---|
| "**4.2** | The authorised share capital is divided into: |

---

**a.** one hundred and eighty million seven hundred and thirty thousand (180730000) ordinary shares; and

**b.** one hundred and eighty million seven hundred and thirty thousand (180730000) preferred shares,

each having a nominal value of twelve eurocents (EUR 0.12).".

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**III.** **A new article 34 will be inserted after article 33. The new article 34 shall come to read as follows:** 

"**TRANSITIONAL PROVISION**

#### ARTICLE 34
Upon the aggregate nominal value of the ordinary shares comprised in Company's issued share capital increasing to an amount of at least eighteen million two hundred and seventy-five thousand one hundred and forty-two euro (EUR 18,275,142.00):

------

---

| | |
|:---|:---|
| ![](image00001.jpg) | ![](image00001.jpg) |
|  | 2 |

---

**a.** the Company's authorised share capital described in Article 4.1 shall immediately and automatically increase to an amount of ninety-one million three hundred and seventy-five thousand seven hundred and ten euro (EUR 91,375,710.00); and

**b.** the composition of the authorised share capital described in Article 4.2 shall immediately and automatically be adjusted, such that the authorised share capital shall be divided into:

**a.** three hundred and eighty million seven hundred and thirty-two thousand one hundred and twenty-five (380732125) ordinary shares; and

**b.** three hundred and eighty million seven hundred and thirty-two thousand one hundred and twenty-five (380732125) preferred shares,

each having a nominal value of twelve eurocents (EUR 0.12).

This Article 34 shall lapse and shall no longer form part of these articles of association at

the moment immediately after the increase of the Company's issued share capital as

described in the first sentence of this Article 34 shall have become effective.".

#### FINAL STATEMENTS
Finally, the person appearing declared:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** that the Company's issued capital amounts to eight million six hundred and seventy-five thousand one hundred and forty-three euro and eight eurocent (EUR 8,675,143.08), divided into seventy-two million two hundred and ninety-two thousand
 eight hundred and fifty-nine (72,292,859) ordinary shares, with a nominal value of twelve eurocent (EUR 0.12) each; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** that the person appearing has been authorised by the abovementioned general meeting of shareholders to execute this deed.

The person appearing is known to me, civil law notary.

This Deed was executed in Amsterdam on the date mentioned in its heading.

After I, civil law notary, had conveyed and explained the contents of the deed in substance to the person appearing, the person appearing declared to have taken note of the contents of the deed, to be in agreement with the contents and not to wish them to be read out in full. Following a partial reading, the deed was signed by the person appearing and by me, civil law notary.

------